Mizuho Names EyePoint a Top Biotech Pick Ahead of Pivotal Wet AMD Data

Mizuho has designated EyePoint, Inc. (EYPT) as its top small- to mid-cap biotech pick, highlighting a pivotal clinical trial data release expected next month as a major potential catalyst. The firm sees the upcoming results for Duravyu, EyePoint's therapy for wet age-related macular degeneration, as a key inflection point for the stock's trajectory.

Mizuho's Bullish Thesis

In a recent analyst note, Mizuho raised its price target on EyePoint to $39 from a previous $36, implying a potential upside of 226% from recent trading levels. The firm, which maintains an "Outperform" rating on the stock, increased its probability of success assumption for the drug to 75% from 70% following recent discussions with key opinion leaders and investors.

Analyst Graig Suvannavejh wrote that Duravyu is positioned to become a "best-in-class" product for its indication. Mizuho's model projects the therapy could achieve global peak risk-adjusted revenue of $1.4 billion by 2040. The $39 price target is based on a discounted cash flow (DCF) valuation with a 13% discount rate.

A High-Stakes Data Readout

The near-term focus for investors is the top-line data from the Phase 3 LUGANO study. This is the first of two pivotal non-inferiority trials evaluating Duravyu, a tyrosine kinase inhibitor, as a maintenance therapy for wet age-related macular degeneration (wet AMD).

Ad

Mizuho outlined a highly binary set of potential outcomes for the stock, hinging on the trial's success:

• Positive Data: The firm believes a doubling of the stock price is "achievable." In a more bullish scenario where the probability of success is revised to 85-90%, the valuation suggests an upside exceeding 300%.
• Negative Data: A trial failure could cause the stock to decline to approximately $3 per share, which the analyst estimates as its cash-per-share valuation.

Market Context and Performance

EyePoint's stock has significantly underperformed its peers so far this year, falling 32% year-to-date compared to a 23% gain for the XBI biotech index, according to the report. This sets the stage for a potentially volatile reaction to the upcoming news.

Adding to recent developments, an independent safety committee recommended that EyePoint's Phase 3 trials for Duravyu continue without modification. Separately, the company also saw Stifel initiate coverage with a "Buy" rating and a $40 price target.